Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Costain selected as delivery partner for Urenco at Capenhurst

(Sharecast News) - Costain Group announced on Thursday that it has been selected as the programme delivery partner for Urenco's infrastructure investment at its Capenhurst site in Cheshire. The London-listed firm said the contract, expected to span at least three years, would see it lead and execute a series of upgrades to support Urenco's operations.

It said the Capenhurst facility plays a key role in uranium enrichment for civil nuclear power, supplying fuel for low-carbon electricity generation in the UK and internationally.

The partnership with Costain was part of Urenco's broader investment in modernising its infrastructure to enhance operational efficiency and support long-term growth.

Costain said it would oversee the integration and delivery of various infrastructure improvements, with contracts to be awarded under the framework over the programme's duration.

"Costain has a long and successful track record in delivering critical national infrastructure that creates a sustainable future," said chief executive officer Alex Vaughan.

"This new role is an example of our strategic focus on growth in strong markets and building a resilient customer mix.

"We will draw on our expertise to ensure predictable, best-in-class delivery for Urenco, as we create a more prosperous, resilient and decarbonised UK."

At 0935 GMT, shares in Costain Group were up 0.47% at 106.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.